미국의 임상 검사 서비스 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 서비스 프로바이더별, 용도별, 부문별 예측(2025-2033년)

Market Size & Trends:

The U.S. clinical laboratory services market size was estimated at USD 9.42 billion in 2024 and is projected to register a CAGR of 5.07% from 2025 to 2033. The market is primarily driven by the increasing burden of chronic diseases, which has intensified the demand for routine and specialized diagnostic testing across care settings. Rising emphasis on early diagnosis and preventive screening has further accelerated the use of clinical laboratory services, particularly for conditions such as diabetes, cardiovascular disorders, and cancer.

In addition, the growing volume of sample testing has led to notable improvements in data management and sample preparation, supporting more efficient laboratory workflows and broader test availability. These enhancements are helping laboratories reduce turnaround times, improve diagnostic accuracy, and handle rising demand across various healthcare settings. Integration of automated systems and digitized reporting tools is also strengthening operational capacity, enabling faster delivery of results and better coordination between clinicians and lab professionals.

The market is also witnessing growing interest from new entrants aiming to capitalize on the sector's strong potential. Driven by the sector's lucrative prospects, new entrants are actively investing in the U.S. For instance, in February 2023, Dutch biotech firm Detact Diagnostics established a new laboratory at Keene State College under a two-year rental agreement. Similarly, in May 2021, Neuberg Diagnostics launched a U.S. lab focused on next-generation sequencing (NGS) and molecular diagnostics-key areas for precision medicine and early disease detection. These investments reflect the expanding scope of specialized testing and the increasing role of innovation in shaping future clinical laboratory services.

Moreover, the evolving regulatory environment and focus on value-based care are further influencing the development of clinical laboratory services in the U.S. Laboratories are increasingly aligning with quality standards set by organizations such as CLIA and CAP to maintain compliance and enhance credibility. At the same time, payers' emphasis on cost-effectiveness and clinical utility encourages labs to adopt more targeted testing strategies. This shift reinforces the need for evidence-backed diagnostics that support clinical decision-making and contribute to improved patient outcomes and optimized healthcare spending.

Prior to the COVID-19 pandemic, over 13 billion clinical tests were conducted annually across more than 200,000 CLIA-certified laboratories, highlighting the essential role of diagnostics in the healthcare system. This infrastructure plays a key role in managing chronic conditions, with nearly 60% of the U.S. population living with at least one chronic disease as of 2022, according to the National Association of Chronic Disease Directors. The clinical demand for routine and specialized testing continues to rise with the country's aging population and the shift toward preventive care.

The pandemic further underscored the critical role of diagnostics, with over 1.17 billion COVID-19 tests performed in the U.S. by March 2023. This surge in testing capacity has strengthened public health preparedness and accelerated investment in lab infrastructure. New entrants are actively tapping into the market's potential, such as Detact Diagnostics, which established a laboratory at Keene State College in February 2023, and Neuberg Diagnostics, which launched a U.S. lab for next-generation sequencing and molecular diagnostics in May 2021. In addition, ProPhase Labs introduced DNA Complete, Inc. in November 2024, a direct-to-consumer DNA testing platform reflecting the market's growing orientation toward personalized diagnostics. Rising cancer incidence-projected to exceed 2 million new cases in 2024-further reinforces the ongoing demand for advanced laboratory services, particularly in oncology-focused testing.

U.S. Clinical Laboratory Services Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. clinical laboratory services market report based on test type,application, and service provider:

• Test Type Outlook (Revenue in USD Million, 2021 - 2033)
• Genetic Testing
• Clinical Chemistry
  • Routine Chemistry Testing
  • Therapeutic Drug Monitoring Testing
  • Endocrinology Chemistry Testing
  • Specialized Chemistry Testing
  • Other Clinical Chemistry Testing
• Medical Microbiology Testing
  • Infectious Disease Testing
  • Transplant Diagnostic Testing
  • Other Microbiology Testing
• Hematology Testing
• Immunology Testing
• Cytology Testing
• Drug of Abuse Testing
• Other Esoteric Tests
• Service Provider Outlook (Revenue in USD Million, 2021 - 2033)
• Hospital-Based Laboratories
• Stand-Alone Laboratories
• Clinic-Based Laboratories
• Application Outlook (Revenue in USD Million, 2021 - 2033)
• Bioanalytical & Lab Chemistry Services
• Toxicology Testing Services
• Cell & Gene Therapy Related Services
• Preclinical & Clinical Trial Related Services
• Drug Discovery & Development Related Services
• Other Clinical Laboratory Services

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Type
  • 1.2.2. Service Provider
  • 1.2.3. Application
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in U.S.
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test Type outlook
  • 2.2.2. Service Provider outlook
  • 2.2.3. Application outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Clinical Laboratory Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in the field of clinical testing
    • 3.2.1.2. Growing prevalence of target diseases coupled with rising demand for early disease diagnostic tests
    • 3.2.1.3. Introduction of novel solutions
    • 3.2.1.4. Outbreak of COIVD-19 pandemic
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Presence of stringent regulatory framework
• 3.3. U.S. Clinical laboratory services market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Clinical laboratory services market: Test Type Estimates & Trend Analysis

• 4.1. Test Type Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. U.S. Clinical laboratory services market by Test Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Genetic Testing
    • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Clinical Chemistry
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.2. Routine Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.3. Therapeutic Drug Monitoring Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.4. Endocrinology Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.5. Specialized Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2.6. Other Clinical Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Medical Microbiology Testing
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.2. Infectious Disease Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.3. Transplant Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3.4. Other Microbiology Testing Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Hematology Testing
    • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.5. Immunology Testing
    • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.6. Cytology Testing
    • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.7. Drug of Abuse Testing
    • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.8 Other Esoteric Tests
    • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Clinical Laboratory Services Market: Service Provider Estimates & Trend Analysis

• 5.1. Service Provider Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. U.S. Clinical laboratory services market by Service Provider Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Hospital-Based Laboratories
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Stand-Alone Laboratories
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Clinic-Based Laboratories
    • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Clinical Laboratory Services Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. U.S. Clinical laboratory services market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Bioanalytical & Lab Chemistry Services
    • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Toxicology Testing Services
    • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Cell & Gene Therapy Related Services
    • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Preclinical & Clinical Trial Related Services
    • 6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Drug Discovery & Development Related Services
    • 6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Eurofins Scientific SE
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. QIAGEN NV
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Quest Diagnostics Incorporated
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. OPKO HEALTH, INC.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Charles River Laboratories International, Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. ARUP LABORATORIES
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Sonic Healthcare
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Neogenomics Laboratories
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Fresenius Medical Care
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Siemens Medical Solutions USA, Inc.
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. SYNLAB International GmbH
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Mayo Clinic Laboratories
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives
  • 7.3.17. Unilabs
    • 7.3.17.1. Company overview
    • 7.3.17.2. Financial performance
    • 7.3.17.3. Product benchmarking
    • 7.3.17.4. Strategic initiatives